



Dear _____,

We are inviting you to be part of a year-long research study.

This study is being done to see if a drug called belimumab, which is already being prescribed for another autoimmune disease, can help people with interstitial lung disease (ILD) caused by rheumatoid arthritis, systemic lupus erythematosus, polymyositis, dermatomyositis, antisynthetase syndrome, Sjogren's syndrome, or mixed connective tissue disease. ILD causes inflammation and scarring (lung fibrosis) that makes it difficult for the lungs to get enough oxygen. The study drug has not been approved to treat ILD.

Study tests, doctor visits, and the study treatment (belimumab or the placebo) will be provided at no cost to you. Travel expenses for you and a caregiver to be able to attend study visits will be reimbursed.

What happens during the study?

The study has 3 main parts.

Screening Period	Study Treatment Period	Safety Follow-up Period
Up to 6 weeks 1 clinic visit	52 weeks 7 clinic visits	8 weeks 1 clinic visit
To check your eligibility for the study	To assess the effectiveness and safety of the study treatment (belimumab or the placebo)	To monitor for any side effects after the Study Treatment Period is finished

If you complete the Study Treatment Period, you may be offered the option to participate in an Extension Study which will provide access to belimumab for at least an additional 52 weeks. If you participate in the Extension Study, you will not need to complete the Safety Follow-up Period.

What is the study treatment?

People in the study will take either the active drug, belimumab, or the placebo, which contains no active ingredients.

Belimumab or the placebo will be given as an injection under the skin once a week. You and the study staff will not know which one you are receiving. You would continue to take your usual medicines.

What else should I know?

We cannot guarantee that you will benefit from taking part in this study. However, knowledge gained from the study will help doctors and researchers learn more about ILD and its treatment.

If you are interested, the study staff will explain the study to you in more detail, answer any questions you have, and see if you qualify to join. Being in a clinical study is voluntary. It is your choice to join, and if you change your mind, you can leave the study at any time.

To speak to a study staff member, call

at _____.

Scan the code or visit
[\[studywebsite.com\]](https://studywebsite.com).

[QR]

GSK - BEconneCTD-ILD -
Participant Letter - 14-AUG-2024 -
English (Principal) - V1.0

BEconneCTD-PL-EnP